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Abstract- Recently prevention of HIV transmission from mother to child by antiretroviral regimens has 
resulted in growing the numbers of HIV exposed but uninfected children (HIV-EU). The aim of present study 
was evaluation of growth and neurodevelopment status among less than 2-year-old HIV exposed uninfected 
children. A cohort study was carried out at Vali-e-Asr Hospital (Tehran-Iran). Thirty-nine HIV-EU neonates 
were recruited (2014 to 2016). Neonates and infants with concern to growth and neurodevelopment status 
were evaluated at 6, 12, 18, and 24 months by an expert physician. Neurodevelopment assessment was based 
on WHO Milestones Chart and Age and Stage Questionnaire. Of all children, 22 were male, and 17 were 
female. Regarding growth indices, although mean birth weight in half of the neonates was lower than normal 
population; no postnatal descending trend was observed in their growth chart. No significant differences were 
found between two groups' height and head circumference. Among the neurodevelopmental parameters 
measured, in 6th months of life, 2 cases had abnormality in the gross motor while at 12 months, 6 cases had 
delay in language, social problem, and motor disorders. At 18 and 24 months, 7 infants showed 
developmental problems of which 71.4% of their mothers were younger than others (age<25 years, P=0.009). 
Prevalence of neurodevelopmental disorders including delay in language, motor, and social domains was 
common among HIV-EU children. As several environmental factors may involve the etiology of 
neurodevelopmental disorders, nearly-full postnatal control and prevention seem necessary.  
© 2018 Tehran University of Medical Sciences. All rights reserved.  
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Introduction 
 
About 70% decreasing trend has been reported 
globally in the incidence of new pediatric HIV 
infections from 2000 to 2015. Some factors like the 
implementation of antenatal screening policies, 
antiretroviral (ARV) drug and prevention activities 
against mother to child transmission are involved in 
such a remarkable achievement (1). The progress in 
mother-to-child preventive strategies results in growing 
numbers of HIV exposed but uninfected (HIV-EU) 
children in these settings (2). 
Although the efficacy of implementation of these 
strategies is well documented, several studies have 
indicated some adverse outcomes among HIV-exposed 
uninfected children including lower birth weight, higher 
infectious morbidity, and mortality during the first two 
years of life compared to HIV-unexposed children. 
Other potential contributing factors like deprivation of 
breastfeeding, early maternal death, abnormalities in the 
immune system and adverse effects of antiretroviral 
medications may also be involved (3,4,5,6). Some 
reports also reported higher risk of neurodevelopmental 
delay, declines in cognitive and motor functioning 
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among HIV-exposed uninfected Infants. On the other 
hand, other studies have demonstrated the safety or mild 
childhood risks related perinatal ARV regimens, 
evidence of increased risk for congenital malformations, 
early childhood cancers or growth abnormalities (7-10). 
Although HIV prevalence was higher among women 
in reproductive age particularly in antenatal period than 
among non-pregnant women, to our knowledge few 
studies are available related to early growth and 
neurodevelopmental patterns of HIV uninfected 
neonates (11-13). This study aimed to determine growth 
and neurodevelopmental status of HIV-EU infants 
during first two years of life to collect some evidence for 
health problems among HIV-EU children.  
  
Materials and Methods 
 
A cohort study was carried out at a referral academic 
center; Vali-e-Asr Hospital affiliated with Tehran 
University of Medical Sciences (Tehran-Iran). Thirty-
nine HIV exposed uninfected neonates born from HIV 
positive mothers were recruited from January 2014 to 
January 2016. All subjects had been visited and 
diagnosed by an expert specialist. Except 6 cases, other 
neonates received 6 weeks' antiretroviral prophylaxis. 
Inclusion criteria were HIV positive mother, children 
with at least 2 negative PCR virology tests and 
gestational age >36 weeks. All parents' participants gave 
written consent and accepted in time of attending for 
receiving routine neonates' visits. Preterm neonates, 
children with congenital, metabolic disorders or 
chromosomal anomalies (based on the results of 
screening test) and any underlying diseases such as 
AIDS-defining illnesses were excluded from the study. 
Moreover, lack of data or parents' unwillingness for 
participation in the study was considered as exclusion 
criteria. Anthropometric data like neonates' weight, 
length, head circumference, the z scores of weight for 
age, length for age, and weight for length were 
determined at birth, 6, 12, 18 and 24 months by standard 
anthropometric techniques and equipment based on 
standardized protocol. Neurodevelopment assessment 
such as cognition status, fine and gross motor function, 
speech and language ability, problem-solving and social 
development based on World Health Organization 
(WHO) Milestones Chart and Age and Stage 
Questionnaire (ASQ) were also evaluated by an expert 
specialist during first 2 years of children's life. ASQ 
questionnaire has been translated into Persian and 
validated for Iranian children by Child Bureau of Iran 
Health Ministry. Conclusions were stated as normal or 
abnormal according to cut off point for each domain and 
age. All collected data were recorded in some checklists. 
Our primary outcome was assessment of the growth and 
neurodevelopmental trend among 2-year-old HIV 
exposed but uninfected children.  
 
Data analysis 
The software package SPSS version 19 was used to 
perform the statistical analysis. Data are presented as 
mean±standard deviation for continuous variables and 
frequency/percentage for categorical variables. The t-
test and Chi-square analysis were applied to analyze the 
correlations and relationships between variables. The 
study had a power of 80% and P<0.05 was used as 
statistical significance. 
 
Ethical considerations 
Participants were assured about the confidentiality of 
the personal information. No extra cost was imposed on 
subjects, and they also had their right to discontinue the 
study course whenever they wished. Ethics approval for 
the study was obtained from the institutional review 
board of Tehran University of Medical Sciences 
according to Helsinki declaration.  
 
Results 
 
Thirty-nine uninfected newborns born to HIV 
seropositive mothers (mean age 28±5.2 years old) 
entered the study and were assessed with regard to 
growth and neurodevelopmental outcomes. Of all 
mothers, one of them had smoking, and 82% had no 
history of any underlying diseases; however, anemia 
was reported in 2 cases (5.12%). Of all neonates, 22 
cases were male, and 17 cases were female (Table 1). 
No neonates suffered from chromosomal anomalies and 
metabolic disorders. Type of delivery in all subjects was 
cesarean section except one case. Two cases (5.1%) had 
gestational age between 36 and 37 weeks and 10 cases 
(26%) were low birth weight (<2500 gr). 
Regarding growth indices, although mean birth 
weight in half of the neonates was lower than normal 
population; no postnatal descending trend was observed 
in their growth chart. Newborns' length and head 
circumference were normal at birth and afterward. No 
significant decrements were observed in these 2 
parameters, and neonates did not need any interventions. 
Anthropometrics measurements are shown in table 2.  
In evaluating the neurodevelopmental status of 
infants in 6th months of life, 2 cases showed abnormality 
in gross movement. By 12 months after birth, 1 case had 
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social problem, 2 had abnormal language, 2 cases 
showed combined abnormality in gross movement and 
language and a child showed both social problem  and 
abnormality in language. At age 18 and 24 months, 7 
subjects (17%) had abnormal neurodevelopmental status 
in social and language development. A significant 
inverse correlation was observed between frequency of 
neurodevelopment abnormality and mother's age. This 
risk was notable among children whose mothers were 
younger (age<25 years) (P=0.009). Seventy-five percent 
of mothers who received antiviral medication during 
post-partum period had children with abnormal 
developmental status (P=0.11). Of 6 neonates without 
antiviral prophylaxis, 4 cases (66.7%) showed 
abnormality in neurodevelopmental outcomes (P=0.11). 
Abnormal neurodevelopmental status was observed in 
75% of neonates whose mothers did not receive 
postpartum antiviral medication (P=0.11). 
 
Table 1. Demographic data related neonates and their mothers 
Variables N (%) 
Gender  Male 22 (56.5) Female 17 (43.5  )  
Education  
Lower diploma 16 (42) 
Diploma and higher 23 (58) 
Occupation  Employed 
2 (5) 
Housekeeper 37 (95) 
 
 
Table 2. Indices of growth among neonates with different ages 
24 months 18 months 12 months 6 months At birth Indices of growth variables 
9.8951±2.36 8.4818±5.53 7.5916±4.67 5.3500±3.75 2.8816±.42 Weight (Kg) 
38.45±20.1 36.80±20.62 34.16±30.1 33.50±18.78 34.50±1.84 Head circumference (Cm) 
87.42±3.42 80.50±3.56 74.07±3.61 65.25±3.71 49.37±2.76 Length (Cm) 
 
 
Discussion 
 
Nowadays growing numbers of HIV exposed but 
uninfected (HEU) children show efficient strategies 
against HIV transmission from mother to child. On the 
other hand, recent studies have shown the high 
mortality, risk of poor growth, under-nutrition, 
neurocognitive dysfunction among HEU children that 
may be related to low birth weight, malnutrition, and 
micronutrient deficiencies or recurrent infections. 
Environmental and behavioral factors like exposures to 
antiviral medication, maternal illness or death resulting 
lack of infant care and reduced breastfeeding maybe also 
involved (2,12,14).  
We found that mean birth weights in the half of 
neonates were lower than the normal population, 
however; no postnatal descending trend was observed in 
their growth chart. Moreover, newborns' length and head 
circumference were normal at birth and afterward. These 
findings were confirmed by other studies; Powis et al., 
showed a significant correlation between in 
utero exposure to antiretroviral therapy and low birth 
weight in HIV-uninfected infants born ≥37 weeks 
(P<.001), however during first 6 months of life this 
complication was rapidly corrected (15). Agostoni et al., 
also demonstrated that among HIV exposed uninfected 
infants a rapid weight gain was observed immediately 
after birth and despite negative z scores of mean weight 
for age and length for age at first months, these scores 
changed to positive ranges from the 4th and 9th month, 
respectively (16). As Morden et al., have indicated it is 
supposed that birth weight and feeding modality were 
influential and crucial determining factors for growth 
indices during first 6 months (17). 
Although it has been indicated that all mean scores 
related to cognitive and intellectual function among 
HEU children are higher than same variables in HIV 
infected counterparts (18), results of the present study 
have revealed that HEU children may also be prone to 
some poor neurodevelopmental outcomes. The 
frequency of these disorders were more notable with 
increasing age of children; of all subjects at 6 months of 
age, 2 cases showed abnormality in gross movement 
while at 12 months; 6 cases and at 18 to 24 months, 7 
cases had abnormal developmental status in different 
domains including social problem, language, and gross 
movement. It is supposed that some unfavorable social 
conditions during first two years of life like mother's 
health status, single parenthood, lower family income, 
feeding artificial formulas and infections may be 
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involved in progressive adverse outcomes (16,19). In 
accordance to our results, Kartik et al., demonstrated 
that differences in developmental indices among both 
HIV infected and HIV exposed but uninfected children 
were observed after birth and increased with children's 
age (20). Kerr et al., showed that poor 
neurodevelopmental outcomes were more frequent in 
the group of HIV EU children in comparison with HIV-
unexposed uninfected children; of 166 HEU children 
aged 1-12 years, 81% and 3.3% had abnormality in 
language (P=0.002) and social problem (P=0.002), 
respectively. Moreover, 93% of them needed more care 
by parents (P=0.01) (21). Chase et al., indicated an age-
dependent drop in both mental and psychomotor 
developmental indices in39.5% and 36.8% of 481 HEU 
children aged less than 30 months (9).Williams et al., 
also revealed that of 2680 HIV-uninfected children with 
mean age 2.4 years and positive history antenatal ARV 
exposure, abnormality in Language (13.2%) and 
metabolic disorders (11.4%) were the most common 
adverse outcomes (22). lower scores of 2 neurologic 
examinations with 6 weeks interval were also observed 
in 14% and 28% of 25 seroreverted children aged 3-30 
months by  Knight et al., (23). Van Rie also showed that 
motor delay was significantly more frequent in 35 HIV 
uninfected aged 18 to 72 months in comparison with 
their healthy counterparts, however, delay in language 
and mental disorder was not notable (24). 
We found that frequency of poor 
neurodevelopmental outcomes was significantly higher 
among children with younger mothers (age<25 years) 
(P=0.009). Consistent with our results, Agostoni et al., 
showed more growth and neurodevelopmental 
abnormalities in HEU infants with younger mothers in 
compared to subjects in the reference group (27 vs. 32.5-
year-old, P<0.001) (16). Malee et al., also demonstrated 
that some maternal characteristics might associate with 
the prevalence of HIV and neonates adverse outcomes; 
mothers with several disorders and persistent 
complications were younger compared to those with no 
disorders (19). 
A limitation of our study was few numbers of the 
cases and a long time required for data collection. Multi-
centered data collection in more than one hospital or 
retrograde method (historical cohort study) would be 
beneficial. Moreover, we did not consider some social 
and postnatal factors like the route of feeding, infants' 
metabolic or infectious diseases, low family income, 
maternal comorbid disorders, anxiety and depression, 
psychiatric disorders and medication and/or therapy that 
may adversely affect on the care of children and 
contribute to the persistence of disorders.  
Results of the present study showed that 
neurodevelopmental disorders in different domains 
during the first two years of life were common among 
HIV-EU children. Early-full postnatal control and 
prevention seem necessary. 
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